Catalent Makes Two Key European Appointments in Oral Dose Manufacturing
Catalent Pharma Solutions has made two key appointments at its Schorndorf, and Eberbach, Germany, facilities.
Dr Irmgard Neuper is the new General Manager at Catalent’s Schorndorf facility, which provides large-scale, complex oral solid manufacturing with integrated analytical, development, and packaging services.
Dr Neuper joins Catalent from Sandoz, with 17 years of operating and leadership experience in Technical Operations functions in Austria, the US, Germany and Brazil, where she gained significant expertise in manufacturing, from early pharmaceutical intermediates to finished dosage forms. Her most recent role at Sandoz was as Site Head at the company’s Gerlingen, Germany, facility.
Prior to this, she served in a number of roles at Sandoz, including Global Quality Project Manager; Site Head for Solid Oral Dosage forms and Liquids in Brazil; Head of Production for Frankfurt Industrial products; and Project Manager for R&D at the Geneva, US, site.
Dr Neuper has a PhD in Agricultural Sciences and a Diploma in Engineering for Food and Biotechnology, both from University for Agricultural Sciences, Vienna.
In a second announcement, Luc Burgard will become the new General Manager of Catalent’s 360,000 sq.ft. Eberbach softgel manufacturing facility.
Mr Burgard joined Catalent in October 2011 as European Operational Excellence Leader, based in Beinheim, France, before being appointed as Operations Director at the Eberbach site in April 2013. Prior to joining Catalent, he was employed by Faurecia, a global automotive technology supplier for 9 years, working in progressively senior operational roles including the Global Leader in Engineering Methodologies.
Mr Burgard holds a Bachelor’s Degree in electronics and quality from Cergy-Pontoise University, as well as an Advanced Master’s Degree in innovative design and mathematics from the Institut National des Sciences Appliquées of Strasbourg.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.